科前生物
(688526)
| 流通市值：53.33亿 | | | 总市值：53.33亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 574,896,175.61 | 373,827,539.24 | 227,536,944.76 | 949,742,023.06 |
| 营业收入 | 574,896,175.61 | 373,827,539.24 | 227,536,944.76 | 949,742,023.06 |
| 二、营业总成本 | 419,561,340.78 | 267,836,114.82 | 135,315,536.88 | 524,371,080.48 |
| 营业成本 | 240,210,161.25 | 151,692,522.85 | 81,909,523.78 | 313,671,966.29 |
| 税金及附加 | 8,175,747.39 | 5,234,423.54 | 3,344,201.3 | 6,399,678.69 |
| 销售费用 | 67,117,809.12 | 40,549,016.99 | 22,245,513.12 | 105,203,660.83 |
| 管理费用 | 41,935,887.13 | 29,648,784.13 | 13,429,405.56 | 59,837,555.5 |
| 研发费用 | 89,294,733.71 | 59,446,864.13 | 25,104,400 | 96,411,370.73 |
| 财务费用 | -27,172,997.82 | -18,735,496.82 | -10,717,506.88 | -57,153,151.56 |
| 其中:利息费用 | 217,691.45 | 142,141.28 | 72,173.84 | -1,773,682.84 |
| 其中:利息收入 | 26,980,171.8 | 18,391,939.85 | 10,229,925.76 | 56,421,355.48 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,634,669.26 | 18,336,038.27 | 2,366,175.01 | 33,271,389.35 |
| 加:投资收益 | 6,984,366.22 | 4,523,727.69 | 2,145,490.3 | 7,405,727.22 |
| 资产减值损失(新) | -15,468,727.96 | -8,642,244.07 | -6,310,502.25 | -12,636,565.86 |
| 信用减值损失(新) | -8,397,136.2 | -3,868,090.72 | -7,316,880.5 | 9,693,386.86 |
| 其他收益 | 16,730,749.15 | 13,049,878.98 | 7,096,490.51 | 20,009,419.46 |
| 四、营业利润 | 162,818,755.3 | 129,390,734.57 | 90,202,180.95 | 483,114,299.61 |
| 加:营业外收入 | 94,132.39 | 63,598.91 | 29,913.45 | 222,656 |
| 减:营业外支出 | 1,793,961.3 | 715,912.45 | 127,104.18 | 1,796,169.34 |
| 五、利润总额 | 161,118,926.39 | 128,738,421.03 | 90,104,990.22 | 481,540,786.27 |
| 减:所得税费用 | 16,644,435.78 | 14,014,598.37 | 11,415,862.54 | 64,599,520.14 |
| 六、净利润 | 144,474,490.61 | 114,723,822.66 | 78,689,127.68 | 416,941,266.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 144,474,490.61 | 114,723,822.66 | 78,689,127.68 | 416,941,266.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 146,058,837.04 | 115,723,217.64 | 79,236,163.81 | 418,723,155.8 |
| 少数股东损益 | -1,584,346.43 | -999,394.98 | -547,036.13 | -1,781,889.67 |
| 扣除非经常损益后的净利润 | 122,046,315.94 | 85,696,797.67 | 69,451,904.82 | 351,633,712.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.31 | 0.25 | 0.17 | 0.9 |
| (二)稀释每股收益 | 0.31 | 0.25 | 0.17 | 0.9 |
| 八、其他综合收益 | -15,754,543 | -27,779,257.48 | -7,104,812.04 | 81,279,244.34 |
| 归属于母公司股东的其他综合收益 | -15,754,543 | -27,779,257.48 | -7,104,812.04 | 81,279,244.34 |
| 九、综合收益总额 | 128,719,947.61 | 86,944,565.18 | 71,584,315.64 | 498,220,510.47 |
| 归属于母公司股东的综合收益总额 | 130,304,294.04 | 87,943,960.16 | 72,131,351.77 | 500,002,400.14 |
| 归属于少数股东的综合收益总额 | -1,584,346.43 | -999,394.98 | -547,036.13 | -1,781,889.67 |
| 公告日期 | 2026-10-31 | 2026-08-27 | 2026-04-30 | 2026-04-08 |
| 审计意见(境内) | | | | 标准无保留意见 |